Actualités ProSomnus Inc - OSA | Actions NASDAQ

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

PLEASANTON, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

PLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading...

ProSomnus Reports First Quarter 2023 Financial Results

PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”...

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

PLEASANTON, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

PLEASANTON, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

PLEASANTON, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

PLEASANTON, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the...

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ProSomnus Inc (OSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

OSA Actualités

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

ProSomnus Reports First Quarter 2023 Financial Results

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ProSomnus Inc (OSA) Actualités

ProSomnus Inc (OSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

OSA Actualités

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

ProSomnus Reports First Quarter 2023 Financial Results

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application